

Octreotide (acetate)

Catalog No: tcsc0944



Available Sizes

Size: 10mg

Size: 50mg



Specifications

CAS No:

79517-01-4

Formula:

$C_{51}H_{70}N_{10}O_{12}S_2$

Pathway:

GPCR/G Protein

Target:

Somatostatin Receptor

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 29 mg/mL (26.87 mM)

Alternative Names:

SMS 201-995 (acetate)


Observed Molecular Weight:

1079.29

Product Description

Octreotide acetate, a long-acting synthetic analog of native somatostatin, inhibits **growth hormone**, **glucagon**, and **insulin** more potently.

In Vivo: Octreotide-treated groups show a significant reduction in the tumor volume when compared with saline group. Octreotide-PPSG (1.4 mg/kg, i.p.) shows greater antitumor effect than Octreotide-soln (100 µg/kg, i.p.). Octreotide-treatments results in significant inhibitory effect on the expression levels of SSTR2 and SSTR5 in primary HCC-bearing rats compared with the saline group. Octreotide-PPSG appears to inhibit the expression of SSTR2 and SSTR5 to a greater extent than that of Octreotide-soln treated group^[1]. A test dose of octreotide acetate significantly decreases the serum gastrin level to approximately one third of the baseline in 2 hr and the effect lasted approximately for 6 hr. On day 21, treatment with sustained-release formulation of octreotide acetate (5 mg intramuscular, q 4 wk) is initiated^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!